A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype

• Main Authors: Marina Baretti (Author), Enusha Karunasena (Author), Marianna Zahurak (Author), Rosalind Walker (Author), Yang Zhao (Author), Thomas R. Pisanic 2nd (Author), Tza‐Huei Wang (Author), Tim F. Greten (Author), Austin G. Duffy (Author), Elske Gootjes (Author), Gerrit Meijer (Author), Henk M.W. Verheul (Author), Nita Ahuja (Author), James G. Herman (Author), Nilofer S. Azad (Author)
• Format: Book
• Published: Wiley, 2021-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract We previously reported CHFR methylation in a subset of colorectal cancer (CRC; ∼30%) with high concordance with microsatellite instability (MSI). We also showed that CHFR methylation predicted for sensitivity to docetaxel, whereas the MSI‐high phenotypes were sensitive to gemcitabine. We hy...